Qiagen v. ArcherDX: Federal Circuit Reverses on NGS Library Prep Patents
Qiagen Sciences and five co-plaintiffs brought infringement claims against ArcherDX and The General Hospital Corporation over two next-generation sequencing patents covering targeted DNA/RNA library preparation. The Federal Circuit reversed the lower court decision in a case spanning 712 days, directly affecting Qiagen’s GeneRead and QIAseq product lines.
Federal Circuit overturns NGS library prep infringement ruling against Qiagen
Qiagen Sciences, LLC — together with Qiagen Beverly, Qiagen Gaithersburg, Qiagen LLC, Qiagen NV, Qiagen GmbH, and individual co-plaintiff Jonathan Arnold — filed an infringement action against ArcherDX, LLC and The General Hospital Corporation on 1 September 2023. The dispute centres on two US patents, US10017810B2 and US10450597B2, which protect methods and compositions used in next-generation sequencing (NGS) library preparation and targeted sequencing workflows. The accused products include Qiagen’s GeneRead QIAact Kits, QIAseq Immune Repertoire RNA Library Kits, QIAseq Index Kits for Illumina and Ion Torrent platforms, QIAseq Targeted DNA Panels, and QIAseq Targeted RNAscan Panels.
The Court of Appeals for the Federal Circuit issued its judgment on 13 August 2025, ordering the lower court decision reversed. Reversal at the Federal Circuit means the appellate panel identified reversible legal error in the decision below — whether in claim construction, infringement analysis, or another dispositive issue — and the prior ruling no longer stands. For Qiagen as appellant, the reversal is a significant procedural win; for ArcherDX and The General Hospital Corporation as appellees, the prior favourable ruling has been set aside.
At 712 days, the appeal’s duration is consistent with complex biotechnology cases at the Federal Circuit, where claim construction disputes over highly technical molecular biology terminology routinely extend proceedings. The public record does not disclose whether the Federal Circuit remanded for further proceedings or resolved the dispute outright, nor does it reveal the precise legal ground — claim construction, obviousness, or enablement — on which reversal was ordered. These details, where material, would typically appear in the full written opinion.
Filing to Case Reversed in 712 days
712 days — above the median for Federal Circuit NGS patent appeals
Federal Circuit reverses: what the ruling means for both parties
Reversal means the lower decision is legally nullified
At the Federal Circuit, a ‘REVERSED’ disposition means the appellate panel found reversible error in the lower court’s ruling — the prior judgment no longer has legal effect. Depending on whether a remand was ordered, the case may return to the district court for further proceedings consistent with the appellate court’s analysis, or the reversal may be dispositive. The specific ground (e.g., claim construction error, incorrect infringement standard) would appear in the written opinion.
Reversible error foundQiagen’s appellate challenge succeeds — prior ruling overturned
As the appellant, Qiagen and its co-plaintiffs persuaded the Federal Circuit that the lower court erred. The reversal restores Qiagen’s legal position and, depending on the scope of remand, may reopen the infringement question or resolve it in Qiagen’s favour. This outcome strengthens the enforceability narrative around US10017810B2 and US10450597B2 and may deter competitors from relying on the now-overturned decision as a safe harbour.
Appellant wins on appealArcherDX and General Hospital lose the lower court ruling they relied on
ArcherDX and The General Hospital Corporation, as appellees, had the benefit of the lower court’s decision — now reversed. They face either a remand with renewed litigation risk or a direct adverse outcome, depending on the Federal Circuit’s mandate. At this stage, the appellees’ options are limited: en banc rehearing or certiorari to the Supreme Court, both statistically unlikely to succeed given the Federal Circuit’s low grant rate.
Appellate options narrowedQiagen’s NGS library prep IP gains enforceability momentum post-reversal
The reversal strengthens the commercial position of Qiagen’s QIAseq and GeneRead product IP portfolio. Competitors and licensees in the targeted NGS library preparation space — particularly those developing kits for Illumina and Ion Torrent workflows — should reassess freedom-to-operate assumptions that were predicated on the lower court’s now-overturned ruling. The case signals continued judicial scrutiny of NGS method patents across the precision oncology diagnostics sector.
Enforceability risk elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Qiagen Sciences, LLC | Company | Multinational life-science reagent and NGS kit manufacturer — holder of US10017810B2Search in Eureka ↗ |
| Co-Plaintiff | Qiagen Beverly, LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | Qiagen Gaithersburg, LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | Qiagen, LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | Qiagen, NV | Company | Search in Eureka ↗ |
| Co-Plaintiff | Qiagen, GmbH | Company | Search in Eureka ↗ |
| Co-Plaintiff | Jonathan Arnold | Individual | Search in Eureka ↗ |
| Defendant | Archerdx, LLC | Company | ArcherDX LLC, NGS-based precision oncology diagnostics company; co-defendant The General Hospital Corporation (Massachusetts General Hospital)Search in Eureka ↗ |
| Co-Defendant | The General Hospital Corporation | Company | Search in Eureka ↗ |
| Plaintiff counsel | Andrew Edward Naravage | Attorney | Counsel for Qiagen Sciences, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Brian C. Cannon | Attorney | Counsel for Qiagen Sciences, LLCSearch in Eureka ↗ |
| Plaintiff counsel | David Leon Bilsker | Attorney | Counsel for Qiagen Sciences, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Quinn Emanuel Urquhart & Sullivan, LLP | Law Firm | Representing Qiagen Sciences, LLCSearch in Eureka ↗ |
| Defendant counsel | Daniel M. Silver | Attorney | Counsel for Archerdx, LLCSearch in Eureka ↗ |
| Defendant law firm | McCarter & English LLP | Law Firm | Representing Archerdx, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s mandate — ‘REVERSED’ — reflects an appellate finding of reversible legal error in the proceedings below. At the Federal Circuit, reversal typically follows de novo review of claim construction or a clear-error review of factual findings underlying infringement. The absence of ‘REMANDED’ language in the recorded verdict is notable: it may indicate the appellate court resolved the dispositive issue without returning the case for further fact-finding, though the full written opinion would confirm the precise mandate scope.
US10017810B2 & US10450597B2 — Targeted NGS Library Preparation Methods
US10017810B2 (application US15/269448) and US10450597B2 (application US14/605363) both protect innovations in next-generation sequencing library preparation — the upstream molecular biology steps that determine the accuracy, sensitivity, and specificity of targeted DNA and RNA sequencing assays. These patents cover methods and compositions central to Qiagen’s QIAseq product family, including targeted DNA panels, immune repertoire RNA library kits, and indexing workflows compatible with Illumina and Ion Torrent sequencer platforms.
In the precision oncology and clinical genomics market, library preparation IP has become a key battleground: the ability to reliably enrich and index specific genomic targets drives both diagnostic performance and cost. Qiagen’s assertion of these patents against ArcherDX — a direct competitor in the oncology NGS kit space — reflects the commercial stakes of controlling foundational library prep methodology. The Federal Circuit reversal suggests these patents retain enforceability strength that the lower court may have underweighted, making them material assets for both licensing and exclusivity strategies.
Should your NGS kit pipeline include an FTO against US10017810B2?
Any R&D team or product organisation developing targeted NGS library preparation kits — particularly those designed for Illumina or Ion Torrent platforms, or covering immune repertoire, somatic mutation, or targeted DNA/RNA panels — should conduct or refresh a freedom-to-operate analysis against US10017810B2 and US10450597B2. The Federal Circuit’s reversal means the competitive landscape has shifted: assumptions based on the lower court’s prior ruling no longer provide reliable clearance.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US10017810B2 and US10450597B2 against your product specifications, flag dependent claim risks, and identify design-around opportunities informed by the prosecution history. Given the involvement of multiple Qiagen entities as co-plaintiffs, Eureka can also surface related portfolio filings — including continuations and divisionals — that may extend IP coverage beyond the two asserted patents in this case.
Run a freedom-to-operate analysis on US10017810B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit NGS and genomic sequencing patent appeal cases
Explore Federal Circuit patent appeals involving next-generation sequencing library preparation, targeted genomic panel methods, and precision oncology diagnostics IP.
What this case signals for the NGS library prep IP landscape
The Federal Circuit’s reversal in Qiagen v. ArcherDX reshapes the enforceability calculus for targeted sequencing IP across the precision diagnostics sector.
FTO analyses built on the lower court ruling may now be invalid
Any freedom-to-operate or clearance opinion relying on the now-reversed lower court decision should be revisited. Companies developing targeted NGS kits for Illumina or Ion Torrent platforms — particularly those with products comparable to ArcherDX’s assay workflows — face renewed infringement exposure under US10017810B2 and US10450597B2.
Qiagen’s multi-entity plaintiff structure signals coordinated IP enforcement
The involvement of six Qiagen entities alongside individual inventor Jonathan Arnold suggests a deliberate, coordinated enforcement strategy designed to cover all assignee and licensing interests. This structure is consistent with patent holders seeking to maximise standing and prevent jurisdictional challenges — a pattern worth noting for defendants in the NGS sector.
Qiagen v Archerdx — key questions answered
The Federal Circuit issued a REVERSED disposition in Case 23-2350 on 13 August 2025, nullifying the lower court’s ruling. The reversal confirms the appellate panel found reversible legal error in the proceedings below. The specific ground — whether claim construction, infringement standard, or another issue — would be detailed in the full written opinion. Qiagen and co-plaintiffs were the appellants; ArcherDX and The General Hospital Corporation were appellees.
Qiagen asserted two US patents: US10017810B2 (application US15/269448) and US10450597B2 (application US14/605363). Both relate to next-generation sequencing library preparation methods and compositions. The accused products include GeneRead QIAact Kits, QIAseq Immune Repertoire RNA Library Kits, QIAseq Index Kits for Illumina and Ion Torrent platforms, QIAseq Targeted DNA Panels, and QIAseq Targeted RNAscan Panels.
A Federal Circuit reversal means the lower court decision that ArcherDX previously benefited from no longer stands. Depending on the scope of the mandate, the case may be remanded to the district court for further proceedings, potentially reinstating infringement exposure for ArcherDX’s NGS sequencing products. ArcherDX’s remaining appellate options — en banc rehearing or Supreme Court certiorari — are statistically rare paths to relief.
The General Hospital Corporation (Massachusetts General Hospital) was named as a co-defendant alongside ArcherDX in this infringement action. This is consistent with situations where a research institution has a licensing or inventorship interest in the accused NGS workflows, or where the patented methods are practised in part through the institution’s research or collaborative commercial activities. The public docket does not detail the precise basis for their inclusion.
The appeal ran for 712 days, from filing on 1 September 2023 to the Federal Circuit’s decision on 13 August 2025. This duration is consistent with technically complex biotechnology patent appeals at the Federal Circuit, where claim construction disputes over molecular biology terminology and extensive technical briefing typically extend timelines beyond simpler mechanical or software patent cases.
PatSnap Eureka searches patents and litigation data to answer instantly.